Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction
Author(s) -
Giulio Guagliumi,
Marco A. Costa,
Vasile Sirbu,
Giuseppe Musumeci,
Hiram G. Bezerra,
Nobuaki Suzuki,
Aleksandre Matiashvili,
Nikoloz Lortkipanidze,
Laurian Mihalcsik,
Antonio Trivisonno,
Orazio Valsecchi,
Gary S. Mintz,
Ovidiu Dressler,
Helen Parise,
Akiko Maehara,
Ecaterina Cristea,
Alexandra J. Lansky,
Roxana Mehran,
Gregg W. Stone
Publication year - 2011
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.110.963181
Subject(s) - medicine , stent , myocardial infarction , percutaneous coronary intervention , cardiology , restenosis , bare metal stent , neointimal hyperplasia , target lesion , bare metal , radiology , paclitaxel , optical coherence tomography , drug eluting stent , cancer
The safety of drug-eluting stents in ST-segment elevation myocardial infarction (STEMI) continues to be debated. Pathological studies have demonstrated an association between uncovered struts and subsequent stent thrombosis. Optical coherence tomography can detect stent strut coverage in vivo on a micron-scale level. We therefore used optical coherence tomography to examine strut coverage in patients with STEMI treated with paclitaxel-eluting stents (PES) and bare metal stents (BMS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom